title: [Treatment of metastatic melanoma: are we entering the era of targeted treatment?].
abstract: The treatment of metastatic melanoma has progressed greatly during the last two years. Nowadays melanomas can be divided into molecular subgroups, this being therapeutically relevant. Around 60% of  melanomas show a BRAF mutation and can be treated with selected tyrokinase inhibitors. In addition a CTLA-4-antibody was developed which shuts off the natural immune breaking system resulting in a continuous anti-tumor reaction. Angiogenesis inhibitors have shown there importance in different phase II trials. We hope that this represents only the first step of an individualized treatment for metastatic melanoma.
authors.affiliation: Abteilung Medizinische Onkologie/Hämatologie, Kantonsspital Graubünden.
authors.forename: R
authors.initials: R
authors.lastname: von Moos
authors.forename: R
authors.initials: R
authors.lastname: Cathomas
authors.forename: M
authors.initials: M
authors.lastname: Mark
authors.forename: F
authors.initials: F
authors.lastname: Hitz
mesh_terms: D020533:Angiogenesis Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D060908:CTLA-4 Antigen / Q000037:antagonists & inhibitors; D005544:Forecasting; D006801:Humans; D007211:Indoles / Q000009:adverse effects / Q000627:therapeutic use; D000074324:Ipilimumab; D008545:Melanoma / Q000188:drug therapy* / Q000401:mortality / Q000556:secondary*; D058990:Molecular Targeted Therapy / Q000009:adverse effects / Q000639:trends*; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000401:mortality; D013449:Sulfonamides / Q000009:adverse effects / Q000627:therapeutic use; D015996:Survival Rate; D000077484:Vemurafenib
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D060908:CTLA-4 Antigen; D007211:Indoles; D000074324:Ipilimumab; D013449:Sulfonamides; D000077484:Vemurafenib; C520704:tremelimumab